Mesenchymal Cell Platelet Production via Iron Transport
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing megakaryocytes and platelets are inefficient, requiring extensive resources and time, and existing techniques for thrombopoietin (TPO) production are not practical due to low yields and safety concerns, such as gene introduction and antibody induction.
Innovation Solution
Culturing mesenchymal cells, specifically preadipocytes, in a medium containing an iron ion and an iron transporter, which induces differentiation into megakaryocytes and platelets, and using a predetermined cell-surface marker profile to enhance efficiency, and producing TPO through a similar process, allowing for efficient and safe production without gene introduction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If platelets are produced through blood donation, then platelet supply is available, but storage life is limited to about three days and supply amount varies
Solution Approach 1:
The patent uses the patient's own mesenchymal stem cells to produce platelets, eliminating the need for blood donation and storage. The cells are cultured in vitro to generate platelets on demand, making the system self-sufficient and removing dependency on external blood banks with limited storage capacity.
Solution Approach 2:
The patent changes the production parameters by using specific culture conditions including iron-bound transferrin (10-100 μg/mL), basic fibroblast growth factor (2-20 ng/mL), and thrombopoietin (1-10 ng/mL) to optimize megakaryocyte differentiation and platelet production efficiency, achieving high-yield platelet generation from mesenchymal stem cells.
2Reliability
If platelets are produced from iPS cells, then rejection-free custom-made platelets can be produced, but production time requires at least about 50 days
Solution Approach 1:
Instead of following the conventional path from iPS cells through multiple differentiation stages (which takes 50+ days), the patent inverts the approach by directly using mesenchymal stem cells that can be differentiated into megakaryocytes and platelets in a much shorter time frame while still achieving allocompatible or autologous platelet production that minimizes rejection risk.
Solution Approach 2:
The patent performs preliminary selection and preparation of mesenchymal stem cells with specific surface marker profiles (CD73+, CD90+, CD105+, CD45-, CD34-) before differentiation, ensuring that the cells are pre-conditioned for optimal platelet production and compatibility, thereby reducing the overall production time while maintaining reliability.
3Loss of time
If direct reprogramming of fibroblasts is used, then platelets can be produced in about 14 days, but gene introduction is required which raises safety concerns
Solution Approach 1:
The patent extracts and eliminates the gene transfer step from the direct reprogramming process by using mesenchymal stem cells that naturally possess the capability to differentiate into megakaryocytes and platelets through physiological signaling pathways, thereby achieving rapid platelet production without introducing exogenous genes or viral vectors that could compromise safety.
4Quantity of substance
If conventional platelet production methods are used, then platelets can be obtained, but production efficiency is low requiring tens of thousands of petri dishes
Solution Approach 1:
The patent uses mesenchymal stem cells that exhibit multi-functionality, capable of differentiating into multiple cell types including megakaryocytes and platelets, as well as producing thrombopoietin. This universal cell source eliminates the need for multiple separate culture systems and significantly reduces the number of petri dishes required compared to conventional methods using单一 cell lines.
Solution Approach 2:
The patent merges the functions of platelet production and thrombopoietin production into a single culture system using mesenchymal stem cells. The co-culture or sequential culture of mesenchymal stem cells achieves both megakaryocyte differentiation for platelet generation and TPO secretion, consolidating multiple production functions into one system and reducing overall device complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method enables the rapid and cost-effective production of megakaryocytes and platelets with enhanced thrombus-forming ability and TPO production, reducing the risk of antibody induction and improving platelet supply sustainability.
Implementation Method 1
a medium containing an iron ion and an iron transporter
Data Source
AI summary
Provided is a megakaryocyte and/or platelet production method, enabling to produce a megakaryocyte and/or platelet from mesenchymal cells such as preadipocytes in a relatively short period of time, simply, in a large amount and at lower cost or more efficiently in vitro and a method for producing TPO simply and in a larger amount. A first invention is a method for producing a megakaryocyte and/or platelet, comprising culturing a mesenchymal cell in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting megakaryocytes and/or platelets from a culture. A second invention is a method for producing thrombopoietin, comprising culturing a mesenchymal cell or mesenchymal cell-derived megakaryocyte in a mesenchymal cell culturing basic medium containing an iron ion and an iron transporter and collecting thrombopoietin from a culture. A third invention is a method for producing thrombopoietin, comprising culturing a preadipocyte in a preadipocyte culturing basic medium containing dexamethasone, 3-isobutyl-1-methylxanthine and insulin and collecting thrombopoietin from a culture.